1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
Real-time Euronext Paris  -  04:43 2022-08-10 am EDT
3.162 EUR   -1.50%
08/09European ADRs Move Higher in Tuesday Trading
MT
08/08European ADRs Move Higher in Monday Trading
MT
08/05European ADRs Move Lower in Friday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
2.988(c) 3.27(c) 3.56(c) 3.21(c) 3.162 Last
315 140 272 577 356 613 380 668 71 150 Volume
-6.80% +9.44% +8.87% -9.83% -1.50% Change
More quotes
Estimated financial data (e)
Sales 2022 42,6 M 43,5 M 43,5 M
Net income 2022 -97,5 M -99,7 M -99,7 M
Net Debt 2022 0,50 M 0,51 M 0,51 M
P/E ratio 2022 -0,89x
Yield 2022 -
Sales 2023 55,0 M 56,2 M 56,2 M
Net income 2023 -124 M -127 M -127 M
Net Debt 2023 59,0 M 60,3 M 60,3 M
P/E ratio 2023 -0,90x
Yield 2023 -
Capitalization 146 M 149 M 149 M
EV / Sales 2022 3,44x
EV / Sales 2023 3,73x
Nbr of Employees 297
Free-Float 99,9%
More Financials
Company
Cellectis S.A. is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis S.A. is developing life-changing product candidates utilizing TALEN®, its gene editing... 
More about the company
Ratings of Cellectis S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CELLECTIS S.A.
08/09European ADRs Move Higher in Tuesday Trading
MT
08/08European ADRs Move Higher in Monday Trading
MT
08/05European ADRs Move Lower in Friday Trading
MT
08/05TRANSCRIPT : Cellectis S.A., Q2 2022 Earnings Call, Aug 05, 2022
CI
08/04CELLECTIS S A : PRELIMINARY NOTE - Form 6-K
PU
08/04CALYXT : Q2 Earnings Snapshot
AQ
08/04CELLECTIS S A : Provides Business Update and Reports Financial Results for Second Quarter ..
PU
08/04CELLECTIS S A : Provides Business Update and Reports Financial Results for Second Quarter ..
PU
08/04CALYXT, INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
08/04Cellectis S.A. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
CI
08/04Cellectis S.A. Announces Executive Changes
CI
08/04Cellectis Provides Business Update and Reports Financial Results for Second Quarter 202..
GL
08/04European ADRs Move Higher in Thursday Trading
MT
08/04CELLECTIS S.A. : Half-year results
CO
08/03European ADRs Nudge Higher in Wednesday Trading
MT
More news
News in other languages on CELLECTIS S.A.
08/09Les ADR européens sont en hausse mardi
08/08Les ADR européens progressent lundi
08/05Les ADR européens sont en baisse vendredi
08/05CELLECTIS : activités financées jusqu'à début 2024
08/04Cellectis S.A. annonce ses résultats pour le deuxième trimestre et le semestre clos le ..
More news
Analyst Recommendations on CELLECTIS S.A.
More recommendations
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,21 €
Average target price 10,60 €
Spread / Average Target 230%
EPS Revisions
Managers and Directors
André Choulika Chief Executive Officer & Director
Bing C. Wang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Carrie Brownstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CELLECTIS S.A.-56.85%149
MODERNA, INC.-32.62%71 566
LONZA GROUP AG-26.08%43 806
IQVIA HOLDINGS INC.-17.18%43 579
SEAGEN INC.13.58%32 890
ALNYLAM PHARMACEUTICALS, INC.31.72%27 695